ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Order Full text via Infotrieve
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Agusti, A.
Right arrow Articles by Rodriguez-Roisin, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Agusti, A.
Right arrow Articles by Rodriguez-Roisin, R
Eur Respir J 1993; 6: 1371-1377
Copyright © ERS Journals Ltd 1993

Original Articles

Effect of pulmonary hypertension on gas exchange

AG Agusti and R Rodriguez-Roisin

This paper reviews the effects of pulmonary artery hypertension on gas exchange by exploring three different issues, namely: 1) how does gas exchange behave in diseases characterized by increased vascular tone (primary pulmonary hypertension (PPH), chronic obstructive pulmonary disease (COPD) and interstitial pulmonary fibrosis (IPF)) or decreased vascular tone ("hepatopulmonary syndrome"); 2) how does exercise, as a non-pharmacological tool of increasing pulmonary blood flow, modify gas exchange in these diseases; and 3) how do several drugs that lower (vasodilators) or increase (almitrine) the active component of pulmonary hypertension interact with gas exchange. Available data show that: 1) in PPH a high pulmonary vascular tone enhances gas exchange and when it is lowered, either by oxygen or vasodilators, ventilation perfusion (VA/Q) distributions deteriorate; 2) in COPD a lowered (vasodilators) or augmented (almitrine) active vascular tone is almost invariably paralleled by a deterioration or enhancement of ventilation-perfusion matching, respectively; 3) in IPF an adequate active response of the pulmonary vasculature is essential to maintain gas exchange, both at rest and during exercise; and 4) in patients with liver cirrhosis a low pulmonary vascular tone induces an abnormal VA/Q distribution. In summary, these data show that any situation and/or therapeutic intervention that lowers the active vascular tone deteriorates VA/Q relationships and vice versa. The final effect of pulmonary vascular tone on arterial oxygen tension (PaO2) is less predictable. The reason for this uncertainty is that the actual PaO2 value depends on the interplay of the intra- and extrapulmonary factors that control gas exchange in humans, and not only on the degree of VA/Q mismatching.


This article has been cited by other articles:


Home page
 Eur Respir JHome page
N. Weissmann
Hypoxia-driven mechanisms in lung biology and disease: a new review series of the ERS Lung Science Conference
Eur. Respir. J., April 1, 2008; 31(4): 697 - 698.
[Full Text] [PDF]

Home page
 ChestHome page
K. A. Fisher, D. M. Serlin, K. C. Wilson, R. E. Walter, J. S. Berman, and H. W. Farber
Sarcoidosis-Associated Pulmonary Hypertension: Outcome With Long-term Epoprostenol Treatment.
Chest, November 1, 2006; 130(5): 1481 - 1488.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
S. Roizenblatt, C. Guilleminault, D. Poyares, F. Cintra, A. Kauati, and S. Tufik
A Double-blind, Placebo-Controlled, Crossover Study of Sildenafil in Obstructive Sleep Apnea.
Arch Intern Med, September 18, 2006; 166(16): 1763 - 1767.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
I. van der Lee, P. Zanen, J. C. Grutters, R. J. Snijder, and J. M.M. van den Bosch
Diffusing capacity for nitric oxide and carbon monoxide in patients with diffuse parenchymal lung disease and pulmonary arterial hypertension.
Chest, February 1, 2006; 129(2): 378 - 383.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
A. I. Levin and J. F. Coetzee
Arterial Oxygenation During One-Lung Anesthesia
Anesth. Analg., January 1, 2005; 100(1): 12 - 14.
[Full Text] [PDF]

Home page
 ChestHome page
H. Olschewski, B. Rohde, J. Behr, R. Ewert, T. Gessler, H. A. Ghofrani, and T. Schmehl
Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension
Chest, October 1, 2003; 124(4): 1294 - 1304.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. A. Kandler, K. von der Hardt, S. Mahfoud, M. Chada, E. Schoof, T. Papadopoulos, W. Rascher, and J. Dotsch
Pilot Intervention: Aerosolized Adrenomedullin Reduces Pulmonary Hypertension
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1021 - 1026.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
A.T. Dinh-Xuan, M. Humbert, and R. Naeije
Severe pulmonary hypertension: walking through new paths to revisit an old field
Eur. Respir. J., September 1, 2002; 20(3): 509 - 510.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
H. Olschewski, H. A. Ghofrani, T. Schmehl, J. Winkler, H. Wilkens, M. M. Hoper, J. Behr, F.-X. Kleber, W. Seeger, and for the German PPH Study Group*
Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial
Ann Intern Med, March 21, 2000; 132(6): 435 - 443.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. OLSCHEWSKI, H. ARDESCHIR GHOFRANI, D. WALMRATH, R. SCHERMULY, B. TEMMESFELD-WOLLBRÜCK, F. GRIMMINGER, and W. SEEGER
Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis
Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 600 - 607.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the European Respiratory Society.